SECOND SIGHT MEDICAL PRODUCT (EYES)

US81362J3086 - Common Stock

4.14  -0.22 (-5.05%)

After market: 4.0921 -0.05 (-1.16%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EYES. EYES was compared to 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of EYES is average, but there are quite some concerns on its profitability. EYES has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EYES has reported negative net income.
EYES had negative earnings in each of the past 5 years.
In the past 5 years EYES always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -13.82%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EYES so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

EYES does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EYES has more shares outstanding
There is no outstanding debt for EYES. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 6.02 indicates that EYES is not in any danger for bankruptcy at the moment.
There is no outstanding debt for EYES. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.02
ROIC/WACCN/A
WACC9.3%

2.3 Liquidity

A Current Ratio of 22.15 indicates that EYES has no problem at all paying its short term obligations.
A Quick Ratio of 22.15 indicates that EYES has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 22.15
Quick Ratio 22.15

More info and screens

3

3. Growth

3.1 Past

EYES shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.18%.
EPS 1Y (TTM)-42.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q2.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 25.08% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 102.94% on average over the next years. This is a very strong growth
EPS Next Y96.18%
EPS Next 2Y39.88%
EPS Next 3Y25.08%
EPS Next 5YN/A
Revenue Next Year35.73%
Revenue Next 2Y82.84%
Revenue Next 3Y102.94%
Revenue Next 5YN/A

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYES. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYES. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.22

4.3 Compensation for Growth

A more expensive valuation may be justified as EYES's earnings are expected to grow with 25.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.88%
EPS Next 3Y25.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EYES!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SECOND SIGHT MEDICAL PRODUCT

NASDAQ:EYES (8/30/2022, 7:10:00 PM)

After market: 4.0921 -0.05 (-1.16%)

4.14

-0.22 (-5.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.38M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.82%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 22.15
Quick Ratio 22.15
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-42.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y96.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y